^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    engineered autologous T cells

    i
    Other names: engineered autologous T cells, autologous chimeric T lymphocytes targeted to prostate-specific membrane antigen (PSMA)
    Associations

    News

    Trials
    Company:
    Memorial Sloan-Kettering Cancer Center
    Drug class:
    PSMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    6ms
    Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    cyclophosphamide • engineered autologous T cells
    over1year
    Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    cyclophosphamide • engineered autologous T cells